The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
 
Thierry Facon
Leadership - French Society of Hematology
 
Meletios Athanasios Dimopoulos
Honoraria - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Sanofi; Takeda
 
Xavier P Leleu
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi; Takeda
Travel, Accommodations, Expenses - Sanofi, Janssen, Pfizer
 
Meral Beksac
Honoraria - BMS, Janssen
Consulting or Advisory Role - GSK, Takeda, Amgen, Janssen, Menarini
 
Ludek Pour
No Relationships to Disclose
 
Roman Hajek
Honoraria - Janssen, Amgen, Celgene, BMS, PharmaMar, Takeda
Consulting or Advisory Role - Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, Takeda, GSK, Oncopeptides
Speakers' Bureau - Janssen Amgen Celgene BMS PharmaMar Takeda
Travel, Accommodations, Expenses - Janssen, Amgen, Celgene, Takeda
 
Zhuogang Liu
No Relationships to Disclose
 
Jiri Minarik
Honoraria - Amgen, BMS, Celgene, Janssen, Sanofi, GSK, Pfizer
Consulting or Advisory Role - Amgen, BMS, Celgene, Janssen, Sanofi, GSK
 
Philippe Moreau
Honoraria - CELGENE JANSSEN TAKEDA AMGEN PFIZER ABBVIE SANOFI
Consulting or Advisory Role - CELGENE JANSSEN TAKEDA AMGEN PFIZER ABBVIE SANOFI
 
Joanna Romejko-Jarosinska
Honoraria - AstraZeneca, Gilead, Roche, Janssen, Celgene, Sanofi, Takeda
Consulting or Advisory Role - Swixx BioPharma
Travel, Accommodations, Expenses - Gilead, Roche, Takeda
 
Ivan Spicka
Honoraria - Amgen, Janssen-Cilag, Takeda, BMS, Sanofi
Consulting or Advisory Role - BMS, Amgen, Janssen-Cilag, Takeda, Sanofi, GSK
Travel, Accommodations, Expenses - Janssen-Cilag, Takeda, Sanofi
 
Vladimir I. Vorobyev
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Gilead Sciences; Janssen; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Gilead Sciences; Janssen Oncology; Novartis; Roche; Sanofi; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BeiGene; BioCad; BMSi; Janssen; MSD; Novartis; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca
 
Michele Cavo
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Celgene/Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini Group; Sanofi; Takeda
Consulting or Advisory Role - Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini Stemline, Sanofi, and Karyopharm Therapeutics
Speakers' Bureau - Celgene/Bristol-Myers Squibb; Janssen
 
Hartmut Goldschmidt
Honoraria - Amgen; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); GlycoMimetics Inc. (Inst); Heidelberg Pharma (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); MorphoSys (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Sanofi
Other Relationship - Amgen (Inst); Array BioPharma/Pfizer (Inst); Celgene/Bristol-Myers Squibb (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Sanofi (Inst)
 
Thomas G. Martin
Consulting or Advisory Role - GlaxoSmithKline; Legend Biotech; Pfizer
Research Funding - AMGEN (Inst); BMSi; Janssen Oncology (Inst); Sanofi (Inst)
 
Salomon Manier
Consulting or Advisory Role - Abbvie, Adaptive Biotechnology, Amgen, Celgene/BMS, GlaxoSmithKline, Janssen, Novartis, Oncopeptide, Pfizer, Regeneron, Roche, Sanofi, Takeda
Travel, Accommodations, Expenses - Janssen, BMS, Amgen, Sanofi
 
Marie-France Brégeault
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Sandrine Macé
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Christelle Berthou
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Robert Z. Orlowski
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; AstraZeneca; BioTheryX; Bristol-Myers Squibb; GlaxoSmithKline; IASO Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Meridian Therapeutics; Monte Rosa Therapeutics; Neoleukin Therapeutics; Oncopeptides; Regeneron; Sanofi; Takeda
Research Funding - Asylia Therapeutics, Inc. (Inst); BioTheryX (Inst); CARsgen Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Exelixis (Inst); Heidelberg Pharma (Inst); Janssen Biotech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Asylia Therapeutics, Inc.